• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » First artificial pancreas trial testing in patients' homes at night

First artificial pancreas trial testing in patients' homes at night

June 22, 2012
CenterWatch Staff

For the first time ever, two patients with diabetes were successfully treated overnight in their own homes with the MD-Logic Artificial Pancreas (MD-Logic) system, developed by specialists at Schneider Children's Medical Center of Israel. The test is a major step towards the development of a commercial device for night-time automatic control of a patient's blood glucose levels at home.

Moshe Phillip, MD, the study head, said that the study "is an important message for patients with insulin-treated diabetes and their families. Night-time is a sensitive period of the day where patients are unable to consciously control their blood glucose levels and are therefore exposed to extreme changes. Using the MD-logic system might change their life."

The trial follows a previous successful test that took place on October 9, 2011, simultaneously in Israel, Slovenia and Germany, where 54 diabetics were treated, for the first time in the world, with the MD-Logic system in diabetes camps.

The study is a part of a prospective, crossover, randomized collaborative project is operated by DREAM (Diabetes WiREless Artificial Pancreas ConsortiuM) with teams from three centers: Schneider Children's in Petach Tikva, Israel; the department of pediatric endocrinology, diabetes and metabolism headed by Tadej Battelino at University Children's Hospital in Ljubljana, Slovenia; and the department of pediatric endocrinology and diabetes headed by Thomas Danne at Kinderkrankenhaus auf der Bult from Hannover, Germany.

The MD-Logic Artificial Pancreas system represents an artificial pancreas and is comprised of an off-the-shelf subcutaneous glucose sensor that monitors glucose levels and an insulin pump. The sensor and pump are connected to a computer that programs the patient's information and stipulates the amount of insulin that should be released to the body in order to maintain blood glucose balance. This innovation "closes the loop" between the sensor and the pump, relieving the diabetic from daily treatment while potentially and significantly improving quality of life.

Utilizing the MD-Logic in the patient's home would allow millions of diabetics all over the world to lead a normal life, freeing them from the demanding and burdensome routine of traditional treatment. Moreover, the MD-Logic would reduce patients' fear of hypoglycemia and the risk of episodic unconsciousness and convulsions that might be secondary side-effects of severe hypoglycemia.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing